Trial Profile
Phase II Trial of Thalidomide and Doxil® (Doxorubicin HCL Liposome Injection) in Patients With Androgen Independent Prostate Cancer (AIPC) With a Rising PSA While on Chemotherapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Doxorubicin liposomal (Primary) ; Thalidomide (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 20 Jun 2012 Actual patient number is 40 according to ClinicalTrials.gov.
- 20 Jun 2012 Actual end date (Jan 2012) added as reported by ClinicalTrials.gov.
- 20 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.